DCDaniel R. Connolly

Daniel R. Connolly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel R. Connolly has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Counter-balancing X-linked Mecp2 hypofunction by hyperfunction ameliorates disease features in a model of Rett syndrome: implications for genetic therapies

    by Christopher M McGraw, Sirena Soriano, Hao Shuang, Daniel R Connolly, Ali Chahrour, Zhenyu Wu, Agnes J Liang, Yaling Sun, Jianrong Tang, Rodney C Samaco

    Treating monogenic neurodevelopmental disorders remains challenging and mostly symptomatic. X-linked disorders affecting women such as the postnatal neurodevelopmental disorder Rett syndrome (caused by mutations in the gene MECP2 ) have additional challenges due to dosage sensitivity and to cellular mosaicism caused by random X-chromosome inactivation. An approach to augment MECP2 expression from wild-type cells in RTT may be feasible and simpler than gene replacement but has never been tested due to known toxicity of MECP2 over-expression, as evidenced by the distinct neurological condition known as MECP2 Duplication Syndrome. Here, using genetic techniques, we find that “counter-balancing” Mecp2 -null cells in female Mecp2 -null/+ mice by a complementary population of cells harboring an X-linked transgene associated with 3X normal levels of MECP2 leads to normalization of multiple whole animal phenotypic outcomes without noticeable toxicity. In addition, in vivo LFP recordings demonstrate that counter-balancing Mecp2 loss-of-function improves select within-region and between-region abnormalities. By comparing the counter-balance approach with an approach based on cell autonomous restoration of MeCP2 using an autosomal transgene expressing 2X normal levels of MECP2 in all cells (mimicking gene replacement), we identify neurobehavioral and electrographic features best suited for preclinical biomarkers of a therapeutic response to cell autonomous versus non-cell autonomous correction. Notably, these proof-of-concept findings demonstrate how non-cell autonomous suppression of MeCP2 deficiency by boosting overall wild-type MeCP2 levels may be a viable disease-modifying therapy for RTT, with potential implications for genetic-based therapies of monogenic X-linked disorders. One Sentence Summary: In a mouse model of Rett syndrome, counterbalancing mosaic LOF with complementary mosaic GOF improves phenotypic outcome.

  • Invited Review: Epigenetics in neurodevelopment

    by R.D. Salinas, D. R. Connolly, H. Song

    Neural development requires the orchestration of dynamic changes in gene expression to regulate cell fate decisions. This regulation is heavily influenced by epigenetics, heritable changes in gene expression not directly explained by genomic information alone. An understanding of the complexity of epigenetic regulation is rapidly emerging through the development of novel technologies that can assay various features of epigenetics and gene regulation. Here, we provide a broad overview of several commonly investigated modes of epigenetic regulation, including DNA methylation, histone modifications, noncoding RNAs, as well as epitranscriptomics that describe modifications of RNA, in neurodevelopment and diseases. Rather than functioning in isolation, it is being increasingly appreciated that these various modes of gene regulation are dynamically interactive and coordinate the complex nature of neurodevelopment along multiple axes. Future work investigating these interactions will likely utilize ‘multi‐omic’ strategies that assay cell fate dynamics in a high‐dimensional and high‐throughput fashion. Novel human neurodevelopmental models including iPSC and cerebral organoid systems may provide further insight into human‐specific features of neurodevelopment and diseases.


  • Open Access

    Loss of MeCP2 in the rat models regression, impaired sociability and transcriptional deficits of Rett syndrome

    by Surabi Veeraragavan, Ying-Wooi Wan, Daniel R. Connolly, Shannon M. Hamilton, Christopher S. Ward, Sirena Soriano, Meagan R. Pitcher, Christopher M. McGraw, Sharon G. Huang, Jennie R. Green, et al.

    Mouse models of the transcriptional modulator Methyl-CpG-Binding Protein 2 (MeCP2) have advanced our understanding of Rett syndrome (RTT). RTT is a ‘prototypical’ neurodevelopmental disorder with many clinical features overlapping with other intellectual and developmental disabilities (IDD). Therapeutic interventions for RTT may therefore have broader applications. However, the reliance on the laboratory mouse to identify viable therapies for the human condition may present challenges in translating findings from the bench to the clinic. In addition, the need to identify outcome measures in well-chosen animal models is critical for preclinical trials. Here, we report that a novel Mecp2 rat model displays high face validity for modelling psychomotor regression of a learned skill, a deficit that has not been shown in Mecp2 mice. Juvenile play, a behavioural feature that is uniquely present in rats and not mice, is also impaired in female Mecp2 rats. Finally, we demonstrate that evaluating the molecular consequences of the loss of MeCP2 in both mouse and rat may result in higher predictive validity with respect to transcriptional changes in the human RTT brain. These data underscore the similarities and differences caused by the loss of MeCP2 among divergent rodent species which may have important implications for the treatment of individuals with disease-causing MECP2 mutations. Taken together, these findings demonstrate that the Mecp2 rat model is a complementary tool with unique features for the study of RTT and highlight the potential benefit of cross-species analyses in identifying potential disease-relevant preclinical outcome measures.